Fig. 5

The effects of NZ001 and sorafenib on tumor growth and metastasis in orthotopic mice models of HCC. a Comparison of the inhibitory effects of NZ001 (30 mg/kg/d) and sorafenib (30 mg/kg/d) in the hepa1-6 orthotopic implantation models. Tumor volumes and number of tumor foci in liver were measured and quantified. b The effects of NZ001 and sorafenib on tumor vascularity (CD34), hypoxia (HIF-1α), total-MET and P-MET expression levels were detected by IHC. c Western blot detected EMT markers (E-cadherin, N-cadherin and vimentin), HIF-1α, total-MET and P-MET expression levels in hepa1-6 xenograft tumors treated with sorafenib and NZ001. Data are shown as the mean ± SD. Significant differences were determined using one-way ANOVA. *: P < 0.05; **: P < 0.01; NS: No Significance